Lodz

• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 5 2025-10-07 Major Depressive Disorder
• A study to assess the effect and safety of efgartigimod IV in participants from 12 years to less than 18 years of age with chronic Immune Th … Recruiting
  2025-521055-23-00 10 2025-10-07 Chronic Idiopathic thrombocytopenic purpura
• A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Recruiting
  2024-519795-11-00 4 2025-10-06 Atopic Dermatitis
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• Dose-Selection, Safety and Efficacy Study with Open-Label Extension of Choline Chloride for Injection in Adolescent and Adult Patients with … Recruiting
  2024-519496-26-00 10 2025-09-25 Intestinal Failure
• A Phase 2 Randomized Trial Evaluating Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mass (ARTEMIS) Recruiting
  2024-515610-41-00 4 2025-09-11 Postmenopausal Osteoporosis
• A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-sm … Recruiting
  2024-515853-48-00 5 2025-09-05 advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C … Recruiting
  2024-517968-36-00 5 2025-07-08 non-small cell lung cancer
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE … Recruiting
  2024-512360-55-00 4 2025-06-30 Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
• A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis Recruiting
  2024-511458-32-00 5 2025-06-15 Ulcerative colitis
• An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting
  2024-511166-36-00 5 2025-06-13 Moderate to Severe Plaque Psoriasis
• A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants … Recruiting
  2024-514239-21-00 3 2025-05-21 Spinal Muscular Atrophy
• Long-term Safety and Tolerability of TAK-881 in Subjects with Primary Immunodeficiency Diseases (PIDD) Recruiting
  2023-505946-24-00 5 2025-05-15 Primary Immunodeficiency Diseases
• A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso … Recruiting
  2024-515706-77-00 5 2025-05-08 Moderate to Severe Plaque Psoriasis
• A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn' … Recruiting
  2024-513054-30-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With AS (Aspire) Recruiting
  2024-512600-19-00 5 2025-04-14 Angelman Syndrome
• A dose ranging study to investigate efficacy and safety of subcutaneous TOUR006 compared with placebo in participants 18 to 80 years of age … Recruiting
  2024-514801-69-00 4 2025-04-02 Thyroid Eye Disease
• A study to assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia Recruiting
  2024-515451-38-00 5 2025-02-27 Primary Immune thrombocytopenia (ITP)
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) Recruiting
  2024-514972-42-00 5 2025-02-25 Thyroid eye disease
• A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies. Recruiting
  2024-516869-36-00 1 2025-02-17 Relapsed or refractory B-cell malignancies: chronic lymphocytic leukem
• Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (F … Recruiting
  2023-509434-19-00 5 2025-02-10 Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Showing 97–120 of 898 trials